Caxton Corporation’s Strongbridge Biopharma plc. SBBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-8,024,542
| Closed | -$16.4M | – | 57 |
|
|
2021
Q3 | $16.4M | Sell |
8,024,542
-58,900
| -0.7% | -$137K | 13.27% | 2 |
|
|
2021
Q2 | $24M | Hold |
8,083,442
| – | – | 16.45% | 1 |
|
|
2021
Q1 | $22.3M | Sell |
8,083,442
-6,000
| -0.1% | -$18.1K | 14.49% | 2 |
|
|
2020
Q4 | $19.7M | Hold |
8,089,442
| – | – | 12.25% | 3 |
|
|
2020
Q3 | $17M | Buy |
8,089,442
+1,477,377
| +22% | +$4.98M | 16.02% | 3 |
|
|
2020
Q2 | $25M | Hold |
6,612,065
| – | – | 26.38% | 2 |
|
|
2020
Q1 | $12.5M | Hold |
6,612,065
| – | – | 13.66% | 4 |
|
|
2019
Q4 | $13.8M | Hold |
6,612,065
| – | – | 13.33% | 2 |
|
|
2019
Q3 | $15.8M | Hold |
6,612,065
| – | – | 17.82% | 1 |
|
|
2019
Q2 | $20.7M | Hold |
6,612,065
| – | – | 23.51% | 1 |
|
|
2019
Q1 | $32.9M | Buy |
6,612,065
+8,000
| +0.1% | +$39.4K | 30.56% | 1 |
|
|
2018
Q4 | $29.6M | Buy |
6,604,065
+309,276
| +5% | +$1.51M | 35.89% | 1 |
|
|
2018
Q3 | $30.5M | Buy |
6,294,789
+896,755
| +17% | +$4.59M | 28.22% | 1 |
|
|
2018
Q2 | $32.4M | Buy |
5,398,034
+21,995
| +0.4% | +$161K | 11.44% | 2 |
|
|
2018
Q1 | $47.3M | Sell |
5,376,039
-138,955
| -3% | -$1.04M | 51.34% | 1 |
|
|
2017
Q4 | $40M | Hold |
5,514,994
| – | – | 48.61% | 1 |
|
|
2017
Q3 | $38.1M | Buy |
5,514,994
+120,000
| +2% | +$828K | 38.73% | 1 |
|
|
2017
Q2 | $38.6M | Hold |
5,394,994
| – | – | 60.18% | 1 |
|
|
2017
Q1 | $25.6M | Hold |
5,394,994
| – | – | 73.15% | 1 |
|
|
2016
Q4 | $12.9M | Buy |
5,394,994
+5,359,749
| +15,207% | +$21.9M | 44.17% | 1 |
|
|
2016
Q3 | $184K | Sell |
35,245
-732
| -2% | -$3.3K | 0.82% | 10 |
|
|
2016
Q2 | $143K | Buy |
+35,977
| New | +$170K | 0.16% | 14 |
|
Caxton Corporation's SBBP Position: Q4 2021 in Review
Caxton Corporation sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 8,024,542 shares — an estimated $16.4M sold.
Caxton Corporation first reported a position in SBBP in Q2 2016 and held it in 22 quarters. The position peaked at $47.3M in Q1 2018. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.
- Caxton Corporation reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
- Caxton Corporation sold 8,024,542 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $16.4M.
- Caxton Corporation first reported a position in Strongbridge Biopharma plc. in Q2 2016 and held it in 22 quarters.
- Caxton Corporation's Strongbridge Biopharma plc. position peaked at $47.3M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.
Based on Caxton Corporation's 13F filing for Q4 2021, filed 14 Feb 2022.